The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors
Andrea Boutros(The University of Sydney), Enrica T. Tanda(Ospedale Policlinico San Martino), Dalila Campanella(Ospedale Policlinico San Martino), Maria Pia Pistillo(Ospedale Policlinico San Martino), Anna Morabito(Ospedale Policlinico San Martino), Eleonora Croce(Ospedale Policlinico San Martino), Francesco Spagnolo(Martin University), Barbara Banelli(Ospedale Policlinico San Martino), Edoardo Raposio(University of Parma), Paola Queirolo, Roberta Carosio(Ospedale Policlinico San Martino), Franco Cecchi(Azienda Ospedaliero-Universitaria Careggi), V. Fontana(Ospedale Policlinico San Martino), P. Pronzato(Accademia Nazionale dei Lincei)
Cited by 9
Related Papers
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
|Circulation|2018|837
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|389
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
|Orphanet Journal of Rare Diseases|2015|345
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
|International Journal of Cancer|2005|322